| Vranjes, Zivko |
NCT05622058: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer |
|
|
| Terminated | 1b | 6 | Europe, US, RoW | ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2) | Aileron Therapeutics, Inc. | Prevention of Chemotherapy-induced Myelosuppression | 02/23 | 02/23 | | |
| Rohla, Miklos |
TAILOR-DAPT, NCT05732701: Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions |
|
|
| Recruiting | N/A | 2788 | Europe, RoW | Algorithm-guided DAPT duration, Standard-of-care DAPT duration | Insel Gruppe AG, University Hospital Bern | Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease | 03/25 | 12/26 | | |
| Stanetic, Bojan M |
RS-ACS, NCT05081336: Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry |
|
|
| Recruiting | N/A | 500 | RoW | Statin, Ezetimib, Alirocumab | University Clinical Centre of Republic of Srpska | Acute Coronary Syndrome, Dyslipidemias | 01/23 | 03/23 | | |
TAILOR-DAPT, NCT05732701: Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions |
|
|
| Recruiting | N/A | 2788 | Europe, RoW | Algorithm-guided DAPT duration, Standard-of-care DAPT duration | Insel Gruppe AG, University Hospital Bern | Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease | 03/25 | 12/26 | | |
| Kovacevic-Preradovic, Tamara |
| Active, not recruiting | 2 | 150 | Canada, US, RoW | HBI-3000, sulcardine sulfate, Placebo | HUYABIO International, LLC., HUYABIO International, LLC | Atrial Fibrillation | 06/25 | 06/25 | | |
| Completed | N/A | 42 | RoW | Observational study | Corteria Pharmaceuticals | Heart Failure, Heart Decompensation | 04/23 | 04/23 | | |
